دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sepsis gene signatures over time and space
Monica Wang
doi : 10.1038/s41581-021-00401-x
Volume 17, Issue 4, April 2021, Published 02 February 2021
Biomarker genetics
Susan J. Allison
doi : 10.1038/s41581-021-00400-y
Volume 17, Issue 4, April 2021, Published 29 January 2021
MANBA is a kidney disease risk gene
Ellen F. Carney
doi : 10.1038/s41581-021-00402-w
Volume 17, Issue 4, April 2021, Published 01 February 2021
Proteasome impairment can lead to CKD
Ellen F. Carney
doi : 10.1038/s41581-021-00409-3
Volume 17, Issue 4, April 2021, Published 15 February 2021
Organ protection beyond glycaemic control with SGLT2 inhibitors
Usha Panchapakesan & Carol Pollock
doi : 10.1038/s41581-020-00373-4
Volume 17, Issue 4, April 2021, Published 06 November 2020
Recent clinical trials demonstrated that sodium–glucose co-transporter 2 inhibitors can reduce hospitalization for heart failure and improve hard kidney end points in patients with and without type 2 diabetes mellitus. These observations consolidate the view that organ protection is independent of blood glucose control and mitigation of traditional risk factors.
The seroprevalence of SARS-CoV-2 in patients on haemodialysis
Viyaasan Mahalingasivam & Laurie Tomlinson
doi : 10.1038/s41581-020-00379-y
Volume 17, Issue 4, April 2021, Published 23 November 2020
A new study reports the seroprevalence of SARS-CoV-2 antibodies among a cross-section of patients on haemodialysis and uses these data to estimate seroprevalence in the general US population. Although this study demonstrates the potential of monitoring infectious disease prevalence in dialysis populations, the findings should be interpreted with caution.
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller & Katherine R. Tuttle
doi : 10.1038/s41581-020-00367-2
Volume 17, Issue 4, April 2021, Published 20 November 2020
Clinical trials have demonstrated that glucagon-like peptide 1 receptor (GLP1R) agonists have therapeutic benefits beyond glycaemic control. Here, the authors examine the protective effects of incretin-based therapies in patients with diabetic kidney disease and how the immunomodulatory and anti-inflammatory effects of GLP1 might underlie this protection.
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Eric Jonasch, Cheryl Lyn Walker & W. Kimryn Rathmell
doi : 10.1038/s41581-020-00359-2
Volume 17, Issue 4, April 2021, Published 03 November 2020
The molecular features that define the initiation and progression of clear cell renal cell carcinoma (ccRCC) are being increasingly defined. This Review summarizes common genomic and chromosomal copy number abnormalities in ccRCC, providing a mechanistic framework with which to organize these features into initiating events, drivers of progression and factors that confer lethality.
Here, the authors describe the mechanisms of ultrafiltration during kidney replacement therapy, the effects of ultrafiltration on cardiovascular physiology and the principles of volume management in critically ill patients. They also discuss potential mechanisms that could underlie the association between ultrafiltration rate and organ dysfunction.
Raghavan Murugan, Rinaldo Bellomo, Paul M. Palevsky & John A. Kellum
doi : 10.1038/s41581-020-00358-3
Volume 17, Issue 4, April 2021, Published 11 November 2020
Ultrafiltration in critically ill patients treated with kidney replacement therapy
Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group
Olivia Boyer, Franz Schaefer, Dieter Haffner, Detlef Bockenhauer, Tuula H?ltt?, Sandra Bérody, Hazel Webb, Marie Heselden, Beata S. Lipska-Zi?tkiewicz, Fatih Ozaltin, Elena Levtchenko & Marina Vivarelli
doi : 10.1038/s41581-020-00384-1
Volume 17, Issue 4, April 2021, Published 29 January 2021
Here, experts from the European Reference Network for Kidney Diseases and the European Society for Paediatric Nephrology present recommendations for the management of congenital nephrotic syndrome, including the use of renin–angiotensin system inhibitors, diuretics, anticoagulation and infection prophylaxis.
